3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Small Cell Lung Carcinoma
19
Ovarian Neoplasms
17
Neuroblastoma
15
Fallopian Tube Neoplasms
13
Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Ganglioneuroblastoma
5
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Neoplasm Metastasis
3
Lung Neoplasms
3
Glioma
3
Central Nervous System Neoplasms
3
Sarcoma, Ewing
2
Rhabdoid Tumor
2
Retinoblastoma
2
Medulloblastoma
2
Leukemia, Myeloid, Acute
2
Wilms Tumor
1
Thrombocythemia, Essential
1
SCLC, Extensive Stage
1
SCLC
1
Rhabdomyosarcoma
1
Retinal Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Interventions
Paclitaxel
8
Hyperthermic Intraperitoneal Chemotherapy
6
Mitomycin
5
Cisplatin
5
Fluorouracil
4
Bevacizumab
4
Oxaliplatin
3
Leucovorin
3
Doxorubicin
3
Cytoreduction Surgical Procedures
3
Carboplatin
3
Blood Specimen Collection
3
sodium thiosulfate
2
pembrolizumab
2
Standard of Care
2
Laparoscopy
2
soluble LAG-3 protein, human
1
relacorilant
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
avelumab
1
X-Rays
1
Topotecan
1
Taxes
1
Specimen Handling
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Topotecan
×
1 year
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled